Adicet follows other cell therapy biotechs in autoimmune pivot
Adicet Bio is shelving plans to use its lead asset to treat cancer and instead shifting its target to autoimmune diseases.
The move, disclosed by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
